New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Immutep securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Immutep Limited due to alleged violations of securities laws following the discontinuation of a key clinical trial, which led to a significant drop in the company's stock price [1][2]. Group 1: Investigation Details - The investigation focuses on whether Immutep issued false or misleading statements or failed to disclose important information to investors [2]. - On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa due to a planned interim futility analysis [2]. - Following this announcement, Immutep's American Depositary Receipts (ADRs) fell by more than 82.4% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights free of charge [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Immutep securities may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 2: Company News and Stock Impact - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Class Action Details - Investors who purchased Immutep securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - The law firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Company Developments - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].